Skip to main content
. Author manuscript; available in PMC: 2018 Mar 1.
Published in final edited form as: Curr Radiol Rep. 2017 Feb 21;5(3):15. doi: 10.1007/s40134-017-0207-y

Figure 4. Ferumoxytol shows differential enhancement of hypercellular hematopoietic marrow and tumor.

Figure 4

(a) Coronal and axial 18F-FDG PET/MR in a young adult after chemotherapy shows diffusely hypermetabolic hematopoietic marrow, (b) axial diffusion-weighted MR images and coronal LAVA images in the same patient after intravenous injection of ferumoxytol show homogeneous iron oxide uptake in the bone marrow, as indicated by homogenous hypointense (dark) marrow signal. (c) Coronal ferumoxytol-enhanced T2-weighted fast spinecho scan of the lumbar spine and pelvis in an 11 year-old patient with biopsy-proven Hodgkin’s leukemia shows multiple focal tumor lesions in the bone marrow (arrows). The normal marrow shows negative (dark) ferumoxytol enhancement while focal tumors show little or no ferumoxytol uptake and stand out as hyperintense (bright) lesions.